Page last updated: 2024-11-02

oxidopamine and Hallucinations

oxidopamine has been researched along with Hallucinations in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Hallucinations: Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.

Research Excerpts

ExcerptRelevanceReference
"Studies on Parkinson's disease patients and dopamine-depleted animals indicate that dopaminergic neurons in the retina degenerate due to the genetic and environmental factors that cause dopaminergic neuron loss in the substantia nigra."1.37Minor retinal degeneration in Parkinson's disease. ( Huang, YM; Yin, ZQ, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huang, YM1
Yin, ZQ1

Other Studies

1 other study available for oxidopamine and Hallucinations

ArticleYear
Minor retinal degeneration in Parkinson's disease.
    Medical hypotheses, 2011, Volume: 76, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Hallucinations; Haplorhini; Humans;

2011